Vanguard Global Advisers
SPRY icon

Vanguard Global Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

Vanguard Global Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Hold
26,535
– – ﹤0.01% 2476
2026
Q1 		$213K Buy
+26,535
New +$254K ﹤0.01% 2419

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Global Advisers's SPRY Position: Q2 2026 in Review

Vanguard Global Advisers held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 26,535 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #2476.

Vanguard Global Advisers first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. The position peaked at $213K in Q1 2026. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Vanguard Global Advisers held 26,535 shares of ARS Pharmaceuticals worth $213K as of Q2 2026.
  • Vanguard Global Advisers left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2476 holding.
  • Vanguard Global Advisers first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's ARS Pharmaceuticals position peaked at $213K in Q1 2026.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.